OOIR: Observatory of International Research

Papers

(The H4-Index of Breast Cancer Research and Treatment is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival	119
SGLT1 as an adverse prognostic factor in invasive ductal carcinoma of the breast	89
Effect of metformin and lifestyle intervention on adipokines and hormones in breast cancer survivors: a pooled analysis from two randomized controlled trials	69
Intraoperative assessment of axillary sentinel lymph nodes by telepathology	63
Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer	58
Surveillance mammography after treatment for male breast cancer	56
Prognostic and predictive impact of NOTCH1 in early breast cancer	56
Differential response of luminal and basal breast cancer cells to acute and chronic hypoxia	55
Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis	54
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer	47
Nuclear magnetic resonance-determined lipoprotein profile and risk of breast cancer: a Mendelian randomization study	47
Premenopausal women with breast cancer in the early post-partum period show molecular profiles of invasion and are associated with poor prognosis	45
Inter-reader agreement of breast magnetic resonance imaging and contrast-enhanced mammography in breast cancer diagnosis: a multi-reader retrospective study	44
Temporal patterns of breast cancer incidence, mortality, disability-adjusted life years and risk factors in 12 South American Countries, 1990–2019: an examination using estimates from the global burde	41
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients	36
Methionine restriction exposes a targetable redox vulnerability of triple-negative breast cancer cells by inducing thioredoxin reductase	36
Long-term dietary intervention influence on physical activity in the Women’s Health Initiative Dietary Modification randomized trial	35
Correction: Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy	34
Exploring the intersectionality of race/ethnicity with rurality on breast cancer outcomes: SEER analysis, 2000–2016	34
Uncovering novel pathogenic variants and pathway mutations in triple-negative breast cancer among the endogamous mizo tribe	34
Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial	33
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer	33
Impact of environmental temperature on the survival outcomes of breast cancer: A SEER-based study	32
The association between cirrhosis and outcomes among female patients undergoing surgery for breast cancer in Ontario: a population-based study	31
Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis	30

Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)	29
Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies	28
Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers	28